AZ HB2105

Amends Laws 2023, chapter 139, section 6 to modify the psilocybin research grant program administered by the Department of Health Services.

Adds two new conditions that clinical trials must treat: symptoms associated with long COVID-19 and inflammatory disorders.

Restricts advisory council members from applying for research grants under the program.

Requires physician members of the advisory council to have experience conducting clinical research involving Schedule I controlled substances, removing the previous requirement for a federal license to study psychedelics.

Extends the exemption from lapsing appropriations for psilocybin research monies from fiscal year 2023-2024 until July 1, 2026, and maintains the section's repeal date of June 30, 2026.